When Medicine Becomes the Problem: The Hidden Gambling Epidemic Linked to Parkinson’s Drugs

A BBC investigation reveals how prescription medications meant to help patients with movement disorders have triggered devastating gambling addictions, sexual compulsions, and financial ruin for hundreds of people across Britain.

Lucy couldn’t understand why she’d suddenly developed a gambling problem. For months, she’d been losing thousands of pounds, never imagining her medication might be responsible. Then she read a BBC news article that changed everything.

She’s one of more than 250 people who contacted Noel Titheradge, the BBC’s investigations correspondent, about addictions triggered by a family of drugs prescribed for movement disorders. The medications, called dopamine agonists, are designed to help patients with Parkinson’s disease and restless leg syndrome. But for some, they’ve become a gateway to compulsive behaviors that have destroyed marriages, drained bank accounts, and shattered lives.

Titheradge’s year-long investigation, featured in the Shadow World podcast series ‘Impulsive,’ exposes a troubling pattern. Despite warnings about these side effects being known for more than two decades, many patients say their doctors never warned them about the risks. The drugs were prescribed more than 1.5 million times in the UK last year alone.

‘It’s ruined my life,’ says Emma, who lost at least £30,000 ($37,000) to gambling after being prescribed Ropinirole by GSK. ‘We’re going to be in debt for God knows how long paying it off.’

The investigation reveals that around one in six people who take these medications develop impulse control disorders. That’s far higher than the 1% threshold typically considered ‘common’ for drug side effects. Yet many patients report being blindsided by behaviors completely out of character – from compulsive gambling and shopping to hypersexuality and binge eating.

Freddie’s story illustrates the devastating family impact. When his father Bill was diagnosed with Parkinson’s, the medication initially gave him a new lease on life. He started ticking items off his retirement bucket list – traveling, skydiving, golf. But then Freddie noticed his previously sensible father behaving unusually. The connection between the medication and the behavioral changes only became clear when Freddie spotted his dad’s medication leaflet on the kitchen table, sparking what he describes as a ‘full-blown crisis.’

The science behind these effects is well understood. Dopamine agonists work by boosting dopamine activity in the brain – the same neurotransmitter involved in reward and motivation. While this helps manage movement symptoms, it can also overstimulate the brain’s reward system in susceptible individuals, leading to compulsive behaviors.

What’s particularly troubling is the timeline of corporate knowledge versus public warnings. BBC investigations uncovered that GSK learned of a case linking its drug Ropinirole to what it called ‘deviant’ sexual behavior – including a case of child sexual assault – as early as 2000. Yet warnings about sexual urges didn’t appear on patient information leaflets until 2007.

The human cost extends far beyond individual patients. Among those who contacted the BBC were police officers, nurses, doctors, and even a bank director – people in positions of trust and responsibility whose lives were upended by medication-induced compulsions. Many describe feeling trapped, knowing their behavior wasn’t normal but unable to control it.

Sue’s experience with two different dopamine agonist drugs illustrates the systemic nature of the problem. She says she wasn’t warned about compulsive behavior side effects on either occasion, even mentioning recent gambling behavior when the second drug was prescribed. She went on to accumulate debts of £80,000 ($98,000).

The regulatory response has been sluggish. Despite mounting evidence, the UK’s Medicines and Healthcare Products Regulatory Agency says it has no plans to change its warnings about dopamine agonist drugs. The agency maintains that sexual impulses vary and that a general warning about activities which may be harmful is sufficient.

Meanwhile, legal battles are emerging internationally. A Belgian court acquitted a man who sexually assaulted his four-year-old granddaughter after accepting that Ropinirole contributed to his behavior. In France, a major judgment is expected next month in a case where a man claims he lost €90,000 ($98,000) to gambling and that the drug destroyed his relationship.

The BBC’s investigation has prompted political attention. The chair of the MPs’ Health Select Committee has asked the UK drug regulator to review warnings about these side effects, and the government has called the findings ‘hugely concerning.’

For patients currently taking these medications, the message is clear: don’t stop without consulting a healthcare professional, but be vigilant for any new or escalating impulsive behaviors. The Royal College of GPs says its updated curriculum will now include monitoring for impulsive behavior side effects.

The story of Lucy, Freddie, Emma, and hundreds of others serves as a stark reminder that even well-intentioned medical treatments can have unintended consequences. As Titheradge’s investigation shows, the line between helping and harming can be thinner than we think – and the cost of that distinction, measured in broken families and ruined lives, is often paid by those who can least afford it.